Year: 2012
Type: article
Study design: Observational Study
Abstract: OBJECTIVES: Core CSF changes in Alzheimer disease (AD) are decreased amyloid β(1-42), increased total tau, and increased phospho-tau, probably indicating amyloid plaque accumulation, axonal degeneration, and tangle pathology, respectively. These biomarkers identify AD already at the predementia stage, but their diagnostic performance might be affected by age-dependent increase of AD-type brain pathology in cognitively unaffected elderly. METHODS: We investigated effects of age on the diagnostic performance of CSF biomarkers in a uniquely large multicenter study population, including a cross-sectional cohort of 529 patients with AD dementia (median age 71, range 43-89 years) and 304 controls (67, 44-91 years), and a longitudinal cohort of 750 subjects without dementia with mild cognitive impairment (69, 43-89 years) followed for at least 2 years, or until dementia diagnosis. RESULTS: The specificities for subjects without AD and the areas under the receiver operating characteristics curves decreased with age. However, the positive predictive value for a combination of biomarkers remained stable, while the negative predictive value decreased only slightly in old subjects, as an effect of the high AD prevalence in older ages. CONCLUSION: Although the diagnostic accuracies for AD decreased with age, the predictive values for a combination of biomarkers remained essentially stable. The findings highlight biomarker variability across ages, but support the use of CSF biomarkers for AD even in older populations.
Source: Neurology
Authors: N. Mattsson, E. Rosén, O. Hansson, N. Andreasen, L. Parnetti, M. Jonsson, S.-K. Herukka, W.M. van der Flier, M.A. Blankenstein, M. Ewers, K. Rich, E. Kaiser, M.M. Verbeek, M. Olde Rikkert, M. Tsolaki, E. Mulugeta, D. Aarsland, P.J. Visser, J. Schröder, J. Marcusson, M. de Leon, H. Hampel, P. Scheltens, A. Wallin, M. Eriksdotter-Jönhagen, L. Minthon, B. Winblad, K. Blennow, H. Zetterberg
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funders: Alzheimer's Association, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, Baxter International, Danone, AADC Research Trust, Demensförbundet, Myriad Genetics, European Commission, Trinity College Dublin, Royal Swedish Academy of Sciences, Forskningsrådet för Arbetsliv och Socialvetenskap, Bundesministerium für Bildung und Forschung, Elan, Lundbeckfonden, Eisai, Vetenskapsrådet, Sahlgrenska Universitetssjukhuset, Center for Translational Molecular Medicine, Swedish Brain Power, Hersenstichting, Internationale Stichting Alzheimer Onderzoek, Stiftelsen Psykiatriska Forskningsfonden, Alzheimer Nederland, Merz Pharmaceuticals, H. Lundbeck A/S, Ipsen, National Institutes of Health, Genentech, Avid Radiopharmaceuticals, Sahlgrenska Akademin, National Institute on Aging, Actelion Pharmaceuticals
OpenAlex ID: W2124670646